Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cilansetron.

Kevin W Olden1, Michael D Crowell

  • 1Division of Gastroenterology, University of South Alabama, Mobile, Alabama 36693, USA. kolden@usouthal.edu

Drugs of Today (Barcelona, Spain : 1998)
|January 4, 2006
PubMed
Summary
This summary is machine-generated.

Cilansetron effectively treats irritable bowel syndrome with diarrhea (IBS-D) in men and women. This well-tolerated drug offers a significant advancement for managing IBS-D symptoms and improving patient quality of life.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Detergent-Containing Toothpaste Decreases Esophageal Mucosal Impedance and Alters Salivary Properties in Humans.

Allergy·2026
Same author

Editorial: Gastrointestinal symptoms-A world of differences.

Alimentary pharmacology & therapeutics·2024
Same author

Development and validation of a novel scoring system for bloating and distension: The Mayo Bloating Questionnaire.

Neurogastroenterology and motility·2022
Same author

Diagnostic Evaluation of Gastric Motor and Sensory Disorders.

The American journal of gastroenterology·2022
Same author

Prevalence of Barrett's Esophagus in Female Patients With Scleroderma.

The American journal of gastroenterology·2021
Same author

Paediatric functional abdominal pain disorders.

Nature reviews. Disease primers·2020
Same journal

Monoclonal antibodies for treatment of osteoporosis.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Tebentafusp: a novel drug for the treatment of metastatic uveal melanoma.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Sugemalimab, a novel PD-L1 inhibitor for treatment of advanced or metastatic non-small cell lung cancer.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Secukinumab, ixekizumab, bimekizumab and brodalumab for psoriasis and psoriatic arthritis.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Mitapivat for sickle cell disease and thalassemia.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Cenegermin for the treatment of dry eye disease.

Drugs of today (Barcelona, Spain : 1998)·2023
See all related articles

Area of Science:

  • Gastroenterology
  • Pharmacology

Background:

  • Irritable bowel syndrome (IBS) affects 10-20% of North Americans and Europeans, causing abdominal pain and altered bowel habits.
  • IBS significantly impacts quality of life and incurs substantial economic costs, estimated at $20-30 billion annually in the US.
  • Existing treatments for IBS, particularly IBS with diarrhea (IBS-D), have limitations.

Purpose of the Study:

  • To evaluate the efficacy and safety of cilansetron, a novel 5-HT3 receptor antagonist, for treating IBS-D.
  • To assess cilansetron's effectiveness across a broad spectrum of IBS-D symptoms in both male and female patients.

Main Methods:

  • Phase III clinical trials were conducted to assess cilansetron's therapeutic effects.
  • Patient-reported outcomes and adverse events were monitored throughout the study duration.

Related Experiment Videos

Main Results:

  • Cilansetron demonstrated significant efficacy in relieving a wide range of IBS-D symptoms in both genders.
  • The drug was generally well-tolerated, with constipation being the most common side effect (3-12% at 6 months).
  • Ischemic colitis occurred in a small number of patients but was self-limited and did not require surgery.

Conclusions:

  • Cilansetron represents a major therapeutic advance for patients suffering from IBS-D.
  • Its high efficacy, favorable tolerability profile, and effectiveness in both sexes make it a valuable treatment option.